



2022-2023 IMPACT REPORT

**DRIVING CANCER
RESEARCH
FORWARD:
A COLLABORATIVE
EFFORT**



Cancer
Research Society

RESEARCH IS THE KEY TO OUTSMARTING CANCER

The Cancer Research Society has joined forces with various stakeholders in the Canadian cancer research ecosystem in order to maximize the scope and impact of its investments. Given the urgency to act, collaboration is essential if we are to outsmart cancer.

Manon Pepin
President and Chief Executive Officer
Cancer Research Society

SUMMARY

A message from the
President & Chief Executive
Officer and the Chairman of
the Board of Directors

4

The State of Cancer in Canada

6

➡ CANCER RESEARCH SOCIETY

A Key Player in the
Research Ecosystem

7

2022-2027 Strategic Plan

9

Board of Directors

10

Scientific Advisory
Committee

11

Our Team

12

➡ RESEARCH

Comprehensive Approach

15

Annual Funding Programs

16

Evaluation Committees

18

Targeted Research Programs

19

Importance of Partnerships

20

A Second Record Year

22

➡ FUNDRAISING AND MOBILIZATION

Key Data

24

Signature Events

25

The Challenge Against Cancer
Program

27

➡ FINANCIAL INFORMATION

28

➡ DONORS

Our Commitment to Our Donors

32

Memorial Funds

33

Corporate Donations

34

This Impact Report presents the activities and financial
information of the Cancer Research Society from
September 1st, 2022 to August 31st, 2023

A MESSAGE FROM THE PRESIDENT & CHIEF EXECUTIVE OFFICER AND THE CHAIRMAN OF THE BOARD OF DIRECTORS

We are delighted to present the 2022-2023 edition of the Cancer Research Society (CRS) Impact Report. We concluded another year in which we exceeded our objectives and affirmed our role as a prominent leader in the funding of cancer research in Canada. As we look back, we can be proud of what we have accomplished. We have made significant progress over the past 78 years to improve the prevention, detection and treatment of cancer through research.

A NEW RECORD FOR RESEARCH FUNDING

Despite challenges related to inflation and economic challenges, CRS stayed the course and funded the greatest number of research projects in its history, for a second consecutive year. Building on strategic partnerships and rigorous day-to-day management, CRS increased its investment in research from \$9.8 million in 2020-2021 to \$13.3 million in 2022-2023. **A total of 225 projects received funding to advance cancer research.**

CRS is also proud to encourage the future generation of researchers as they pursue their cancer research careers in Canada. The Next Generation of Scientists Award is a program at the post-doctoral level, the only one of its kind in Canada, designed to facilitate the transition of scientists to their own research laboratory in a Canadian university or research centre. We also launched in the past year a new program: the Doctoral Research Award. We received 170 applications following the launch of this new initiative, confirming the pressing need for funding at the doctoral level.

Our 2022-2027 strategic plan has helped us stay the course and to closely monitor our key performance indicators. Our plan is based on three strategic pillars: improve the visibility of CRS, increase cancer research funding, and maximize the impact of funds allocated to cancer research. **For the 2022-2023 financial year, our revenues were \$37.4 million compared with \$24.1 million in 2021-2022.**

DRIVING CANCER RESEARCH FORWARD: A COLLABORATIVE EFFORT

The theme of this year's impact report is "collaboration". It is a theme that has shaped our work over the past few years and it is clear that working together with stakeholders in the Canadian research ecosystem has allowed us to maximize our impact. Our strategic partnerships with several Canadian foundations and health research institutes are at the heart of our business model, enabling our research investment to have an even greater impact. **More than \$3 million was contributed this year through partnerships to co-fund innovative cancer research across the country.**

Collaboration takes several forms, and we extend our sincere appreciation to our 280,000 donors who contributed to fighting cancer through research. Without your precious help, we would not be able to fulfill our mission.

A huge thank you as well to the organizing committees of our signature fundraising events, participants in our Challenge Against Cancer program, community initiatives and the corporate sponsors who invest in cancer research alongside CRS. You are true partners on the road to success.

We would not be able to fund the best research projects without the sound recommendations made by the members of our Scientific Advisory Committee and the exceptional contribution of the close to 100 researchers and physicians who graciously volunteer their time to evaluate the hundreds of research project applications that we receive every year. This rigorous, transparent, and demanding process is undertaken with the utmost integrity. We are very grateful that you are willing to lend us your expertise to benefit CRS and the scientific community more broadly.

We would be remiss not to mention the exceptional contribution of our Board of Directors, the management team as well as that of all the staff of CRS. We have accomplished so much over the past year!

Now more than ever, our intent is to continue to drive cancer research forward with the same passion and determination that have characterized our efforts to date. By working together, we will outsmart cancer.

Happy reading!



A handwritten signature in black ink that reads "Manon Pepin".

MANON PEPIN
President
& Chief Executive Officer



A handwritten signature in black ink that reads "C. Paupé".

CHRISTIAN M. PAUPÉ
Chairman of the Board of
Directors

CANCER: THE LEADING CAUSE OF DEATH IN CANADA


In 2023, an estimated 239,100 people will have been diagnosed with cancer and 86,700 will have died from the disease.

Given this data, the mission of the Cancer Research Society is rendered all the more relevant. Research is truly the key to changing these statistics.

239,100

CANADIANS RECEIVED A
CANCER DIAGNOSIS IN 2023


Breast, prostate, lung and colon cancers represented close to half of all new cancer diagnoses.



2 out of 5 Canadians will develop cancer in their lifetime.

86,700

CANADIANS DIED FROM
CANCER IN 2023



1 out of 4 people will die of cancer.

Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada. Canadian Cancer Statistics 2023. Toronto, ON: Canadian Cancer Society; 2023.

CANCER RESEARCH SOCIETY

A KEY PLAYER IN
CANADA'S
CANCER
RESEARCH
ECOSYSTEM

78 YEARS
SINCE ITS CREATION

\$388M
INVESTED IN CANCER
RESEARCH SINCE 1945

ABOUT US

Founded in 1945, the Cancer Research Society is one of the only Canadian organizations exclusively dedicated to support research into all types of cancer. Thanks to the generosity of hundreds of thousands of donors and various partners throughout Canada, we have been able to allocate over \$388 million in grants to thousands of Canadian researchers since the CRS was created.

MISSION

Our mission has remained constant throughout our history: exclusively fund research on all types of cancer in order to prevent, detect and treat this illness.

VISION

Research is the key to outsmart cancer.

VALUES

Determination

Since 1945, the Cancer Research Society has worked tirelessly toward one goal: outsmarting cancer.

Passion

The Cancer Research Society works with conviction, discipline and determination to help Canadian researchers find ways to outsmart cancer.

Integrity

The Cancer Research Society respects and protects the interests of its donors by using the funds entrusted to it efficiently and responsibly, according to strict rules of governance.

Innovation

The Cancer Research Society supports innovative projects involving creativity and original ideas, because it is through research that the solutions to cancer will be discovered.

Excellence

Guided by the highest standards and an uncompromising commitment, the Cancer Research Society aims to exceed expectations in research.

Accountability and governance

Donor accountability goes hand in hand with our mission. Without the generosity of our donors, we could not carry out our mission of financing cancer research. As such, we have made it a core principle to ensure that donor dollars are allocated efficiently and effectively.

2022-2027 STRATEGIC PLAN

The Cancer Research Society has developed a 5-year strategic plan which allows us to stay the course. Clear objectives and solid key performance indicators will allow us to increase the impact of our investment in cancer research in Canada.

THREE STRATEGIC PILLARS AND CONCRETE OBJECTIVES THAT GENERATE RESULTS:

1 INCREASING THE CANCER RESEARCH SOCIETY'S VISIBILITY

To increase the CRS's visibility in Canada, we set a target of increasing the number of subscribers to our social media platforms by 10% each year. By 2023, this target had not only been met, but was exceeded, with up to 16% relying on the platform. This definitely has a positive impact on brand recognition and engagement rates.

2 INCREASING FUNDS DESTINED FOR CANCER RESEARCH

In order to increase the funding for research, it is essential to increase revenues and reduce costs. One of the objectives is to increase the number of monthly donors so that by 2027 they represent 7% of our donor base. We aim to accomplish this, among other things by implementing a greater number of digital initiatives. This objective was reached in 2023 and should be exceeded by 2027.

3 MAXIMIZING THE IMPACT OF THE FUNDING DEDICATED TO CANCER RESEARCH

In order to augment the impact of funding dedicated to cancer research, we set an ambitious goal to increase our investment in research by an average of 10% annually over the 5 years. The table below shows that this objective is expected not only to be achieved, but considerably surpassed by 2027.

EVOLUTION OF RESEARCH INVESTMENTS FROM 2020 TO 2023

2020-2021	\$ 9,838,000
2021-2022	\$ 12,461,000
2022-2023	\$ 13,283,000

AN ACTIVE AND DEVOTED BOARD OF DIRECTORS

The Cancer Research Society (CRS) team had the good fortune of being able to rely on the support and dedication of several members of our Board of Directors, under the leadership of Chairman Christian M. Paupe. Their professional experience and their devotion to the cause are exceptional.

This past year, the CRS had the pleasure of welcoming Ms. Annie Marsolais as a new board member. We would like to welcome her to the team.

We would also like to extend our warm thanks to all of the board members for their volunteer commitment.



CHAIRMAN
Christian M. Paupe
Corporate Director



VICE-PRESIDENT & SECRETARY
Heidi Lange, CRHA
Associate, Richter



TREASURER
Marie Valcourt, CPA, CA
Associate, KPMG LLP

BOARD MEMBERS



Peter Clair
Director and Market Lead, National
Accounts, Québec, Scotiabank



Ghassan Deko
President & Chief Executive
Officer, RCAP Leasing Inc.



Benoît Durocher
Executive Vice-President &
Chief Economic Strategist,
Addenda, Capital Inc.



Carson Loh
Regional Vice-President, North Shore
and Tri-Cities Market, RBC Royal Bank
(British Columbia)



Annie Marsolais
Chief Marketing Officer, Business
Development Bank of Canada
(BDC)



Peter McCarthy
Board Vice-President, BMO
Insurance



François Painchaud
Lawyer & Partner, ROBIC



Sean O'Brien
Executive Vice-President,
Operational Efficiency,
iA Financial Group



Joanna Wilson
Executive Vice-President and
National Practice Lead, Health,
Edelman



**Dr George Zogopoulos, M.D., PhD,
FRCS(C), FACS**
Associate Professor of Surgery and
Oncology McGill University,
HepatoPancreatoBiliary and Transplant
Surgery, McGill University Health Center

A DEEPLY COMMITTED SCIENTIFIC ADVISORY COMMITTEE

The Cancer Research Society (CRS) is fortunate to benefit from the insights of a highly committed Scientific Advisory Committee (SAC) comprised of accomplished cancer research experts from various backgrounds who graciously volunteer their time for the cause. The role of the SAC is to advise the CRS on all scientific matters including cancer research priorities, the selection, organization and development of research funding programs, and the development of strategic partnerships.

PRESIDENT



DR MARK BASIK, MD

Hebert Black Professor of Surgical Oncology,
McGill University

Surgical Oncologist, Lady Davis Institute,
Jewish General Hospital

COMMITTEE MEMBERS



JACQUES CÔTÉ, PHD

Full Professor, Department of Molecular
Biology, Medical Biochemistry and Pathology,
Faculty of Medicine, Université de Laval

Canada Research Chair in Chromatin Biology
and Molecular Epigenetics



CHRISTOPHER ONG, PHD

Associate Professor, Department of Urologic
Sciences, University of British Columbia

Senior Research Scientist, Vancouver Prostate
Centre



RAMA KHOKHA, PHD

Senior Scientist, Princess Margaret Cancer
Centre, University Health Network

Full Professor, Department of Medical
Biophysics, cross appointed to the Department
of Laboratory Medicine and Pathobiology,
University of Toronto



MARIE-ÉLISE PARENT, PHD

Professor, Institut national de la recherche
scientifique (INRS), Armand-Frappier Santé
Biotechnologie Research Centre

Elected member of the Scientific Council,
International Agency for Research on Cancer,
World Health Organization



DR. DON MORRIS, MD, PHD

Professor and Department Head, Oncology
Department, Cumming School of Medicine,
University of Calgary

Medical Director of the Tom Baker Cancer
Centre Cancer Care Alberta, AHS, Associate
Senior Medical Director of Cancer Care Alberta



LYNNE-MARIE POSTOVIT, PHD

Professor and Department Head, Biomedical
and Molecular Sciences, Queen's University

A MANAGEMENT TEAM WITH A MISSION

The management team supervises some thirty dedicated employees, all of whom are deeply committed to the mission of the Cancer Research Society.



MANON PEPIN
President &
Chief Executive Officer



TINA MIGNACCA, CPA, CMA
Director,
Finance and Administration



DAJAN O'DONNELL, PhD
Director,
Scientific Affairs and
Partnerships



KOUDJO ONI, MBA
Director,
Revenue Development



ODILE RIVARD
Director,
Communications and
Marketing

THE FACES BEHIND THE CAUSE

We would like to thank all of our employees for their commitment, passion and dedication. Each of them made a difference on a daily basis so that we can outsmart cancer through research.



RESEARCH



A COMPREHENSIVE APPROACH TO CANCER RESEARCH

The Cancer Research Society (CRS) takes seriously its pivotal role in the Canadian cancer research ecosystem by promoting a global approach. It now funds initiatives covering the entire spectrum of scientific research: fundamental, translational and clinical.

One of the strategic pillars identified as part of CRS 2022-2027 planning process is to maximize the impact of funds allocated to cancer research. It is therefore pursuing its original mission of funding fundamental research through its annual programs, but moving towards supporting translational and clinical research through targeted programs.

THE FUNDED PROJECTS COVER THE ENTIRE SPECTRUM OF SCIENTIFIC RESEARCH

**FUNDAMENTAL
RESEARCH**
Understanding the biology

**TRANSLATIONAL
RESEARCH**
Develop treatments/tests

**CLINICAL
RESEARCH**
Develop and conduct
clinical trials

EXPLORATORY RESEARCH

TARGETED TREATMENT

THREE ANNUAL FUNDING PROGRAMS, A SINGLE MISSION: SUPPORTING RESEARCHERS THROUGHOUT ALL STAGES OF THEIR CAREERS

Our annual research grant and scholarship programs support hundreds of scientists at different stages of their careers. That includes promising students, early, mid-career and established researchers, all of whom are dedicated to making significant advances in the prevention, detection, and treatment of all types of cancer.



ANNUAL FUNDING PROGRAMS

2020-2021

67

2021-2022

80

2022-2023

90

A new record for the number of Operating Grants awarded within a year!

DOCTORAL CANDIDATES



Doctoral Research Award

170 APPLICATIONS RECEIVED!

NEW!

This new program invests strategically in the future of cancer research. By financing PhD students, we aim to encourage the next generation of researchers to excel in innovation and cutting-edge cancer research.

→ [READ THE ARTICLE](#)

POSTDOCTORAL FELLOWS



Next Generation of Scientists Award

\$850,000 OVER 3 YEARS (2023-2025)
AWARDED TO 5 NEXT GENERATION SCIENTISTS

This unique program aims to support and encourage the most promising postdoctoral researchers to start their careers at a Canadian university.

→ [MEET THE 5 RECIPIENTS](#)

RESEARCHERS



Operating Grants


\$10.8 MILLION OVER 2 YEARS (2023-2024)
AWARDED TO 90 RESEARCHERS

The annual Operating Grants Competition is the principal means by which CRS fulfills its mission to support fundamental and early translational cancer research on all types of cancer, ultimately contributing to advances in the prevention, detection and treatment of this disease.

→ [MEET THE 90 RECIPIENTS](#)

EVALUATION COMMITTEES

The success of our three annual programs would not be possible without the participation of 100+ researchers and doctors who volunteer their time to evaluate the most promising research projects we receive each year. We offer them our wholehearted thanks for their invaluable contributions.



“Having received funding from the Cancer Research Society prior to attending my first panel review meeting, I came to see first-hand the rigorous review process undertaken by the CRS to fund the most impactful research. The high level of organization by the CRS staff along with the dedication of the reviewers and the support of the public make CRS well positioned to make a significant contribution to advancing cancer research.”

Testimonial from one of our committee members

TARGETED RESEARCH PROGRAMS

\$750,000

FOR RESEARCH INTO DRUG REPURPOSING

The Cancer Research Society has awarded two new grants as part of its UpCycle Program. The grants total \$750,000 over a two or three-year period. The goal is to reposition existing drugs for new cancer therapies, thereby accelerating the discovery of new treatments while optimizing financial resources.

[→ READ THE ARTICLE](#)

\$3 MILLION

FOR BLOOD CANCER RESEARCH

Over 155 000 Canadians are faced with various types of blood cancer.

To address this reality, the Cancer Research Society and the Leukemia & Lymphoma Society of Canada are investing in blood cancer research by supporting 15 research projects, each benefitting from \$200,000 over a two-year period.

[→ READ THE ARTICLE](#)

\$1 MILLION

FOR BRAIN CANCER RESEARCH

There are some 55,000 Canadians living with brain cancer and over 120 distinct types of brain tumors. Joining forces, the Cancer Research Society and Brain Canada have created an exceptional grant worth \$1 million dollars over a three-year period for translational research on brain cancers.

[→ READ THE ARTICLE](#)

5 CLINICAL TRIALS

FOR RESEARCH INTO BILIARY TRACT, OVARIAN, VULVAR, BLOOD AND PEDIATRIC CANCERS

The Cancer Research Society is committed to financially supporting a wide range of projects covering the entire spectrum of cancer research aimed at outsmarting cancer. While maintaining its traditional investment in fundamental research, the CRS is now expanding its support for clinical research by funding clinical trials led by academic researchers.

This evolution is a testament to our ongoing commitment to support innovative projects that can have a direct impact on cancer patients. As part of our 2022-2027 strategic plan, we have set a target of funding one researcher-led clinical trial every two years. We have not only met this goal, but we have also surpassed it with five clinical trials currently underway covering various types of cancer (biliary tract, ovarian, vulvar, blood and pediatric).

This diversity of clinical trials led by researchers demonstrates our desire to explore varied and innovative solutions to improve treatments for patients with cancer.

INCREASING OUR IMPACT THANKS TO PARTNERSHIPS

By consolidating our efforts through exceptional partnerships, we are doing all that we can to make every donation a powerful catalyst to benefit cancer research. This collaboration considerably amplifies our global impact to outsmart various types of cancer that are often under-funded.

\$3.3 MILLION FROM OUR PARTNERS



\$410,000 FROM OUR MAJOR DONORS

Andy and Léna Chabot Fund

Aristotle Fund

Cancer Research Society's Environment Cancer™ Fund, funded in part by Read for the Cure

Charlotte Légaré Memorial Fund

Herbert J. Davies Memorial Fund

Michael O'Gallagher Memorial Fund

Rob Lutterman Memorial Fund

Steven E and Scott Drabin Research Fund

Succession Helen Lenore Bailey

Suzanne et Louis Daubois Memorial Fund



"Charities have increasingly looked at partnerships with others to leverage their investments, with the Cancer Research Society (CRS) leading the way on this front and enabling smaller-sized charities to fund mandate-aligned research."

Canadian Cancer Research Alliance, 15-Year Report (published in 2022)

”

TESTIMONIALS FROM OUR PARTNERS

Thanks to our partners. As the saying goes, **“Alone, we go faster. Together, we go further.”**

“Ovarian Cancer Canada is proud of its long-standing partnership with the Cancer Research Society in funding the very best in ovarian cancer research. Ovarian cancer is a disease that has been overlooked and underfunded for far too long. By partnering with the Cancer Research Society we are filling a gap in critical research that can transform lives.”

Tania Vrionis, CEO, Ovarian Cancer Canada

“Thanks to a long-standing research funding partnership with the Cancer Research Society, now in its fourth grant cycle, The Leukemia & Lymphoma Society of Canada has been able to increase its investment in blood cancer research in Canada. In 2023 alone, our alliance resulted in a commitment of \$3 million over two years to a total of 15 researchers at a dozen universities across the country. Partnerships such as this increase the impact of our funding, helping to advance our mission of finding a cure for all 137 types of blood cancers and improving the quality of life of Canadians affected by blood cancers.”

Paul O’Connell, Research Program Lead, The Leukemia & Lymphoma Society of Canada

“Collaboration is key in the fight against brain cancer, and Brain Canada is honoured to stand alongside CRS in our pursuit of transformative research. Through our combined commitment to cutting-edge brain research, we are accelerating progress in preventing, detecting, and treating this complex disease.”

Viviane Poupon, PhD, Brain Canada President & CEO

“Partnerships are critical to accelerate progress across all domains of cancer research. Our longstanding, fruitful partnership with the Cancer Research Society (CRS) has enhanced scientific excellence and capacity building within the Canadian cancer research landscape through many initiatives, including the CRS Operating Grant competition and the inaugural Doctoral Research Awards.”

Dr Fei-Fei Liu, Scientific Director, CIHR Institute of Cancer Research

“Our longstanding partnership with the Cancer Research Society is a testament to our shared determination to make a meaningful difference in the lives of those affected by the disease. In this alliance, we are united by a shared vision: a world where every person can live without fearing the burden of breast cancer. Every step we take together strengthens our commitment to the cause, and it is with immense pride that we continue our mission side by side.”


Karine-Iseult Ippersiel, President & CEO, Quebec Breast Cancer Foundation

A SECOND CONSECUTIVE RECORD YEAR FOR FUNDING CANCER RESEARCH!

225
PROJECTS
FUNDED

\$13.3
MILLION
AWARDED IN CANCER
RESEARCH GRANTS

NUMBER OF CANCER RESEARCH PROJECTS FUNDED
BY THE CRS BETWEEN 2020 AND 2023



ANNUAL FUNDING PROGRAMS

Operating Grants

170

Next Generation of Scientists Award

12

Scholarships for undergraduate students

6

TARGETED PROGRAMS

Upcycle: Drug Repurposing

2

Metastatic Breast Cancer

2

Ovarian Cancer

10

Brain Cancer

2

Blood Cancers

15

Clinical Trials

5

Translational Research Partnership Program

1

TOTAL NUMBER OF RESEARCH PROJECTS FUNDED

225

INVESTMENT BY SECTOR

IMPACT

2020-2021

2021-2022

2022-2023

Prevention

\$2,508,000

\$2,346,000

\$2,481,000

Detection

\$620,000

\$1,970,000

\$912,000

Treatment

\$6,710,000

\$8,145,000

\$9,890,000

TOTAL

\$9,838,000

\$12,461,000

\$13,283,000

FUNDRAISING AND MOBILIZATION



FUNDRAISING AND MOBILIZATION

Our fundraisers and mobilization efforts are essential to fulfilling our mission to fund the best cancer research projects.

Thousands of donors, volunteers, partners, organizing committees and dedicated participants mobilize around these activities. It is thanks to them that we are able to meet our objectives.

We offer them our wholehearted thanks for their precious and invaluable contributions.

\$13.3 MILLION

NET AMOUNT COLLECTED DURING OUR
FUNDRAISING ACTIVITIES

280,000

COMMITTED DONORS
ACROSS CANADA

2,000

PARTICIPANTS & VOLUNTEERS
FOR OUR EVENTS



\$10.4 MILLION
DIRECT MARKETING



\$1.2 MILLION
SIGNATURE EVENTS



\$1 MILLION
CHALLENGE AGAINST CANCER
PROGRAM



\$546,000
DIGITAL CAMPAIGNS



\$180,000
COMMUNITY EVENTS

SIGNATURE EVENTS

Year after year, the Cancer Research Society organizes signature events with the support of invaluable partners and organizing committees. These events bring together hundreds of committed donors around large-scale activities to benefit the cause.

\$1.2 MILLION

IN 2023



URBAN BBQ \$700,000



A new record was set for the 9th edition of the Urban BBQ! Under the theme “Around the world”, the event gathered some 1,000 guests and raised a record net amount of over \$700,000.

[➔ READ THE ARTICLE](#)



CYCLO GOLF CLASSIC \$205,000

Scotiabank.

BMO Insurance

For the 28th year, the Classic took place in three cities in the province of Quebec: Montreal, Sherbrooke and Quebec City. The formats differ from one city to another, but the objective remains the same throughout: supporting cancer research.

[➔ READ THE ARTICLE](#)

SIGNATURE EVENTS (CONTINUED)



ACCORDS CÉLESTES \$200,000



The 5th edition of the Accords Célestes evening brought together hundreds of attendees who experienced an unforgettable evening where gastronomy, wine and music harmonized, all for the benefit of cancer research.

[➔ READ THE ARTICLE](#)



READ FOR THE CURE 165,000 \$



Penguin
Random House
Canada



The 15th edition of Read for the Cure was held in Vancouver, Toronto, as well as virtually. Some 1,000 literature enthusiasts came together to benefit the CRS's Environment-Cancer Fund.

[➔ READ THE ARTICLE](#)

A \$1 MILLION RECORD YEAR FOR RESEARCH!

99
PARTICIPANTS

575 km
TRAVELLED

7
DESTINATIONS

755,000
STEPS



Contact Amérique
Voyage

CHALLENGE AGAINST CANCER

We are proud to announce that our Challenge Against Cancer program allowed us to raise the incredible net sum of \$1 million for cancer research in 2023. Previously known as the CRS Challenge, the program has changed name to the Challenge Against Cancer and now bears a new brand image.

The focus, however, remains the same; surpassing **oneself in a unique experience while raising funds to advance cancer research.**

The year 2023 was marked by a return to international destinations and the resumption of travel that had been postponed as a result of the pandemic. Seven remarkable destinations were in the spotlight: Jordan, Italy, Switzerland, Norway, Canada (Newfoundland), Peru and India.

We would like to congratulate the participants for having taken up the challenge and we thank them for the energy they put into supporting our mission!

➔ [READ THE ARTICLE](#)



DID YOU KNOW?

Our spokesperson, André Robitaille took part in the Challenge against cancer in India in June 2023. He captured the images that you can discover in this video.

➔ [SEE THE VIDEO \(ONLY IN FRENCH\)](#)

FINANCIAL INFORMATION

SOUND FINANCIAL MANAGEMENT

Despite a year marked by inflation, the generosity of donors was still quite apparent. The results reflect the success of initiatives implemented by the Cancer Research Society team with the invaluable support of its partners and volunteers. The financial information for the fiscal year from September 1st, 2022 to August 31st, 2023 demonstrates sound financial management.

SUMMARY OF REVENUES AND EXPENSES

FROM SEPTEMBER 1ST, 2022 TO AUGUST 31ST, 2023
(in thousands of dollars)

\$37.1 M

Research program commitments spread over several
years up to 2028

REVENUES	2023	2022
Annual campaigns	23,653	23,597
Major & planned gifts	2,782	2,050
Benefit events and others	4,042	2,502
Contributions to research	2,239	2,007
Realized income for investments	2,095	2,310
Unrealized investment income (loss)	2,597	(8,323)
Other revenues	0	3
	37,408	24,146
EXPENSES		
Annual campaigns	12,694	12,286
Major & planned gifts	206	189
Benefit events and others	1,837	1,225
Administration	1,512	1,355
Depreciation of fixed assets	53	60
	16,302	15,115
SURPLUS AVAILABLE FOR RESEARCH	21,106	9,031
GRANTS & RESEARCH SCHOLARSHIPS (including related expenses)	13,283	12,461
EXCESS (SHORTFALL) OF REVENUES OVER EXPENSES	7,823	(3,430)

SUMMARY OF THE STATEMENT OF FINANCIAL CONDITION

FROM SEPTEMBER 1ST, 2022 TO AUGUST 31ST, 2023
(in thousands of dollars)

ASSETS	2023	2022
Cash	6,714	10,822
Accounts receivable	61	276
Prepaid expenses	215	294
Other short term assets	118	108
Short term investments	5,000	0
	12,108	11,500
Investments	49,023	41,284
Fixed assets	242	275
	61,373	53,059
LIABILITIES		
Accounts payable and accrued liabilities	2,067	787
Deferred contributions – short term	682	1,246
	2,749	2,033
Deferred contributions	0	209
Lease inducement	75	91
	2,824	2,333
FUND BALANCES		
Allocated funds	5,668	6,626
General funds	52,881	44,100
	58,549	50,726
	61,373	53,059

Member of:

IMAGINE
CANADA

DONORS

**280,000 OF
YOU MADE A
DONATION IN
2023!**

At the Cancer Research Society, we know how privileged we are to have the generous support of our donors. Their donations allow us to fund the country's best cancer research projects and it is thanks to their support that we can fulfill our mission of outsmarting cancer!

OUR COMMITMENT TO OUR DONORS

1

Your gifts will be used for the sole purpose of supporting our mission: funding research on all types of cancer to help prevent, detect, and treat this disease.

2

We will strive to keep our cost of fundraising as low as possible, while delivering the greatest impact.

3

Information about your donation will be handled with respect and with confidentiality to the extent provided by law.

4

You can be assured that our methods of fundraising are constantly reviewed, ethically-based, and minimize cost while maximizing impact.

5

You will receive acknowledgment and recognition in a timely manner.

6

If you have questions, comments, or feedback you can expect prompt, transparent, truthful, and forthright answers.

MEMORIAL FUNDS

**73 DONATIONS
VALUED AT OVER
\$2.5 MILLION**

Each year, generous people choose to make a legacy donation to cancer research. It is a gesture filled with hope for a better world where cancer is no longer a terminal disease.

A donation in your will is an important means of support for the Cancer Research Society and helps us to pursue our mission of funding the best research projects to prevent, detect and treat cancer.

For more information about this type of donation, visit our website.

[!\[\]\(f8acdbcc5d87d7690232b09b183a85d5_img.jpg\) VISIT OUR WEBSITE](#)

You can also contact us at
1 866 343-2262 or at
info@src-crs.ca

We would like to thank each of the following people for their posthumous donation. It is a precious legacy for Canadians and a mark of trust in the Cancer Research Society.

Françoise Asselin

Stephen Oliver Byrne

David Joseph Crowley

John Dlusy

Maud and Christina Duncan
Charitable Foundation

Connie Fenney

Marketa Goetz-Stankiewicz

Richard K. Guest

Christiane Guirao

Guy Harvey

Muriel Inez Hirons

Jeanne Laperrière

Susan E. Lennie

Ken & Anne-Marie Lucas

Betty Helen MacGregor

Carol Ann Milner

Mary Moore

Norma McLean Charitable Fund

Yvan Pineau

Elaine Hope Robertson

Lise St-Jean

CORPORATE DONATIONS

\$2.3 MILLION

Thank you to all of the organizations that believe in our mission! Your support makes a real difference and allows us to fund the best research projects to counter cancer.

\$100,000 AND UP

BMO Banque de Montréal / BMO Assurance-vie / BMO Gestion Mondiale d'actifs / BMO Mastercard

Fondation Famille Léon et Diane Gosselin

The Molson Foundation
NU-B Inc.
Penguin Random House Canada

RBC Banque Royale / RBC Marchés des Capitaux / RBC Gestion Patrimoine / RBC Dominion Valeurs Mobilières / Groupe Vachon / Groupe Shapiro / PH & N / Le Groupe Kent / Morris & Bergeron / Gestion Gilles E. Richer / Groupe Pat Savoia

\$50,000 TO \$99,999

Banque Scotia

Caisse de bienfaisance des employés et retraités du CN
Fédération des caisses Desjardins Innovairre Studios inc.

\$25,000 TO \$49,999

3515877 Canada inc.

Econo-Malls Management

Fondation Bergeron-Jetté

Fondation Cure Foundation

Fondation Sandra et Alain Bouchard Raymond

Chabot Grant Thornton

\$10,000 TO \$24,999

Administration portuaire de Montréal - Le Grand Quai

Air Canada

Almadev Inc.

Arbell Electronics

Auto Parc Stanley

BLP Avocats | Lawyers

Congregation of the Marist Sisters

Delta/Air France/KLM

Fasken Martineau DuMoulin

Fondation Denise et Guy St-Germain

Fondation Jacques Francoeur

Fondation Jacques Nolin

Fondation Lise et Giuseppe Racanelli

Genesis Holding Ltd.

Groupe de Courtage Omni Ltée / Groupe Geloso

Groupe Deschênes inc.

Groupe Mach

IA Groupe Financier

Ivanhoé Cambridge inc.

KRB Avocats

LiUNA Local 183

Maud and Christina Duncan
Charitable Foundation

Nuera Industriel

Pyrogenesis inc.

ROBIC

SFL Gestion de Patrimoine

SNC-Lavalin

Société des alcools du Québec

TD Securities / TD Gestion de Placements

The Cole Foundation

The Ken and Roma Lett Foundation

Tidan inc.

Trudel Immeubles inc.

Unifood inc.

Wellington Laboratories inc.

Wertman Development Corporation

\$5,000 TO \$9,999

9014-4304 Québec inc.

A.M. Déjeuner et Dîner

Accord Financier

Addenda Capital

Alre Properties

Assistenza International

Benny & Frères inc.

Bombardier

Borden Ladner Gervais LLP

Brigil

Canada College

Canadian Bank Note Company Ltd.

Canderel Management inc.

Carbonleo Immobilier

CGC Charitable Foundation

Chambre de commerce italienne au Canada

Club Med

Civdev

Corealis Pharma inc.

Corporation BCF inc.

Crowe BGK

Davies Ward Phillips & Vineberg

DLVRD Logistics

Engage

enostore	Company (Canada) inc.	Amgen Canada	Dentons Canada
Federal Real Estate Group	Osler, Hoskin & Harcourt LLP	ARX Capital	Deux Mille Foundation
Fidelity Investments Canada ULC	PC Dupuis	Association des débardeurs de Pointe-au-Pic	Developpement signature
Financière Sun Life	P&R Desjardins Construction inc.	Au Vieux Duluth	Econoplus
Foodtastic (Second Cup)	Parade Leasing	Avila Investments Ltd	EFFIX marketing
Freedom International Brokerage Company	Prince Logistics Services	BC2 Groupe Conseil	Enostore
Fuel It	Richcopter	BDO Canada	Ercon Welding inc.
G2S TOBEQ inc.	Sandalwood Managment	Bryan Ventures Incorporated	Ernst & Young s.r.l./ S.E.N.C.R.L.
Genatec inc.	Shaker Franchiseur	CAD Railways Industries (Oaklins Canada)	Estampro
Germain Larivière	Société de gestion Cogir s.e.n.c.	Caisse Desjardins des Deux-Rivières de Sherbrooke	Faith Lutheran Church
Gestion Immobilière Luc Maurice inc.	Spiegel Sohmer	Calgary Foundation	Fiera Immobilier
Gestion Luc Rodrigue (2019) inc.	Stokes	Canada ICI Capital	Fondation Aide à la jeunesse
Gilbert Séguin Guilbault Avocats	The Charles Norcliffe Baker & Thelma Scott Baker Foundation	Caprea Experts Immobilier	Fondation Céline & Jacques Lamarre
Gloria Baylis Foundation	Trac-World Freight Services inc.	Castel Development	Fondation Denise et Robert Gibeau
Gowling WLG (Canada) LLP	Transport Alexcalibur inc.	Cercle Filles d'Isabelle # 715	Fondation Éric Archambault
Hello Fresh	VA Capital	Charities Aid Foundation of Canada	Fondation Lévesque Demers
Hoogan et Beaufort	White Star Capital	Chiasson Gauvreau inc.	Fondation Réal et Chantal Mimeault
Hornoi Leasing Ltd		CI Investments	Fonds de solidarité FTQ
IMKT Direct Solutions Corp.		CIBC	Fonds Dynamique
Industrielle Alliance - Groupe financier	\$1,000 TO \$4,999	Claridge Real Estate	G M L Mechanical Ltd.
J. R. Armstrong Family Foundation	1833 Asset Management LP	C07 Technologies	Gabriel Turgeon inc.
JDF Stratégies	A&F Sound Investments Inc.	Coal Town Fisheries Limited	Gascon et Associés
Lagoon Seafood	ABMS évaluateurs agréés-Chartered appraisers	Complexe Funéraire Yves Légaré	Gemme Canadienne
Les Immeubles Marc Saulnier	adMare BioInnovations	Conseillers Immobiliers GWL inc.	Gentile Venues & Catering
Les Résidences Soleil	AEDN	Construction CPB inc.	Gestion Canaan
Levy Salis	AGF Investment inc.	Copper Core Limited	Gestion Casavant
MD Financial Management Inc	AgroFusion	Crofton Moore	Gestion David Proulx inc.
Métro Richelieu Inc	Alfid Services Immobiliers Ltée	D.B. Crook Accounting Prof. Corp.	Gestion Gauthier Lépine inc.
Miller Thomson S.E.N.C.R.L.	Aliments Pimentel inc.	Daniel I. Blumer Professional Corporation inc.	Gestion Raymond Brodeur inc.
Mobilia Interiors inc.	Aliments Rose Hill Foods inc.	Demers Beaulne	Gestion Rosaire Dubé Inc.
MSC Mediterranean Shipping			Getpaq

GLT + inc.	La Fondation Desjardins	Octantis - Agence numérique	St-Pierre & Associés
GPL-Gallagher	La Fondation du Grand Montréal	OEC Overseas Express Consolidators Montreal inc.	Strathmore Landscape Contractors [1997] Ltd.
Grenier Gagnon	La Fondation Jean-Luc Gravel et Brigitte Breton	Oeuvres Caritatives des Filles de Jésus, Canada	Surpresseur 4S
Griva-Pete Holdings inc.	Lajoie Distributions Conseils	Otera Capital inc.	Télesystème Ltée
Groupe BLC	Le Cabinet de relations publiques NATIONAL	Patrick Morin inc.	Terrestar Solutions
Groupe Cabico	Le Groupe Altus Ltée	Perry and Ilana Shak Family Foundation	The Canada Life Assurance Company
Groupe Desgagnés inc.	Les Augustines de la Miséricorde de Jésus	Pertinence Media	The Carol Sharyn Tanenbaum Family Foundation
Groupe Focus	Les Constructions Reliance du Canada Ltée	Petra Ltée	The DP Martin Family Foundation
Groupe Immobilier Pertel inc.	Les Développements P.A.T.	PharmaCos Machinery inc.	The Klass Foundation
Groupe Lebel inc.	Les distributions Malbert	Pierre Seccareccia FCPA FCA Administrateur de sociétés	Timex Realty Corporation
Groupe Molesini inc.	Les équipements C.M.	Placements Mackenzie	Toulon Development Corporation
Groupe Petra Ltée.	Les Immeubles Di Ciccio	Placements ND Bakos inc.	Transcontinental / TC Premedia
Groupe Sanimax	Les Missionnaires Oblates De St-Boniface	Prévost Notaires inc.	Transfab TMS
Groupe Somavrac inc.	L'Express du Midi inc.	ProAccess DPS	Trouvailles à Bas Prix
GSH	Life Sciences Manager (Canada) inc.	Produits pétroliers Norcan s.e.n.c	Urgence Marine inc.
Gym Fit Forme	Logistec Corporation	Province de Saint-Joseph/Serv. St-Cœur-de-Marie	Usinage D.D.R. inc.
H S D Investment Ltd.	Lohn Foundation	Québec International	Videoville Showtime inc.
H Van Leeuwen Landscaping Ltd.	Marché Labonté	Quincaillerie Demers inc.	Volaille Régale Poultry inc.
Homeocan	Markham Waterloo Mennonite Conference	R.M. Specialty Cars inc.	Voysis
Hotel Espresso Montreal	Masdel inc.	Régulvar inc.	Wadera inc.
Hub International	Matco Packaging inc.	RGA - Reinsurance Group of America	Westwood Mechanical inc.
HVAC inc.	MC Finance inc.	Rosetown Farming Co. Ltd.	Wharf Tire & Mechanical [2006] LTD.
Inovia Capital	Media Groupe	Rousseau Métal	White Powder Coating Ltd.
Invera inc.	Mercan Capital	Société en Commandite D.D.O.	Worth Capital Management
Ipsos Facto Investissement/Immobilier	Michel Rhéaume Investissement Ltée	Société professionnelle DL inc.	Wyalta Resources Ltd.
ITI International inc.	Midas Canada inc.	Soeurs de l'Institut Jeanne D'Arc	Yaksa
Jarislawsky Fraser	Minicucci Architecte	Soeurs Missionnaires de Notre-Dame des Anges	Yale Properties
Jesta Capital Corporation	NAI Commercial	Sphere Media	
Kelson Financial	Nam Polymers inc.	Stanford Properties Group inc.	
Kingstar Genetic Par: Richard Roy	Noda Capital		
L.R.D. Financing inc.	Natlex		
La Céleste Vins et Spiritueux	Norton Rose Fulbright Canada		

LOOKING TOWARDS THE FUTURE

In light of the achievements and results that have been presented to you, the Cancer Research Society will continue its commitment to the advancement of cancer research in Canada with conviction and dedication. We are privileged to be able to count on the support of thousands of donors across Canada, as well as the collaboration of several partners. The CRS will continue to innovate and excel to strengthen its role as a leader in Canada's research ecosystem. It will pursue its mission by supporting the most promising research projects to benefit all Canadians.



**MONTREAL**

625 President-Kennedy Avenue,
Suite 402
Montreal (Quebec)
H3A 3S5

OTTAWA

P.O. Box 4613, Station E
Ottawa (Ontario)
K1S1P7

Telephone : 514 861-9227

Toll Free: 1 866 343-2262

info@src-crs.ca

CancerResearchSociety.ca



Charitable Registration No.119153229RR001

ISSN 1920-8995 – Legal Deposit– Bibliothèque nationale du Québec, 2023